Traveka Wealth LLC Has $484,000 Stake in AstraZeneca PLC (NASDAQ:AZN)

Traveka Wealth LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,211 shares of the company’s stock after purchasing an additional 195 shares during the quarter. Traveka Wealth LLC’s holdings in AstraZeneca were worth $484,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of AZN. Oppenheimer & Co. Inc. raised its position in shares of AstraZeneca by 14.9% during the fourth quarter. Oppenheimer & Co. Inc. now owns 16,574 shares of the company’s stock worth $1,116,000 after purchasing an additional 2,150 shares during the period. Prudential PLC purchased a new stake in AstraZeneca in the 4th quarter valued at $366,000. Lighthouse Investment Partners LLC purchased a new stake in AstraZeneca in the 4th quarter valued at $421,000. Vista Investment Management increased its position in shares of AstraZeneca by 36.4% during the 4th quarter. Vista Investment Management now owns 14,487 shares of the company’s stock valued at $976,000 after purchasing an additional 3,864 shares during the last quarter. Finally, Ethic Inc. grew its stake in shares of AstraZeneca by 10.7% during the 4th quarter. Ethic Inc. now owns 86,975 shares of the company’s stock worth $5,858,000 after acquiring an additional 8,394 shares during the period. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Trading Down 0.3 %

Shares of AZN stock traded down $0.26 during trading hours on Tuesday, reaching $76.61. The company’s stock had a trading volume of 776,834 shares, compared to its average volume of 5,160,846. The stock has a market capitalization of $237.53 billion, a P/E ratio of 37.68, a P/E/G ratio of 1.43 and a beta of 0.46. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The firm’s fifty day simple moving average is $81.59 and its 200 day simple moving average is $77.60. The company has a current ratio of 0.89, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.01. AstraZeneca had a return on equity of 29.34% and a net margin of 13.11%. The company had revenue of $12.45 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same period in the previous year, the company posted $1.08 earnings per share. The firm’s revenue was up 9.1% on a year-over-year basis. Equities research analysts expect that AstraZeneca PLC will post 4.08 EPS for the current year.

AstraZeneca Cuts Dividend

The company also recently declared a Semi-Annual dividend, which was paid on Monday, September 9th. Investors of record on Friday, August 9th were given a dividend of $0.49 per share. The ex-dividend date of this dividend was Friday, August 9th. This represents a dividend yield of 1.8%. AstraZeneca’s dividend payout ratio is presently 48.04%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on AZN shares. Deutsche Bank Aktiengesellschaft downgraded AstraZeneca from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Barclays upgraded AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. TD Cowen raised their target price on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, Citigroup upgraded AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.